Get the Stockscreener App
220.75
0.32%
0.71
After Hours:
220.58
-0.17
-0.08%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $220.75, with a volume of 4.87M.
It is up +0.32% in the last 24 hours and down -1.15% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$220.04
Open:
$219.53
24h Volume:
4.87M
Relative Volume:
0.86
Market Cap:
$390.15B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
166.57
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-1.42%
1M Performance:
-1.15%
6M Performance:
+14.71%
1Y Performance:
+24.90%
1-Day Range:
$215.85
$220.75
1-Week Range:
$215.85
$237.04
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
220.75 | 388.90B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,077.19 | 967.52B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
213.65 | 505.28B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
141.61 | 272.12B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.26 | 271.01B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Trump administration strikes deal with AbbVie to cut costs of certain drugs - WCVB
Key facts: AbbVie signs Medicaid deal; banker charged with insider trading; UAE launches mental health campaign - TradingView — Track All Markets
AbbVie and Trump administration reach agreement on drug prices, tariffs - Daily Herald
AbbVie news: Trump administration strikes deal with North Chicago-based company to cut costs of certain drugs - ABC7 Chicago
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight - GlobeNewswire Inc.
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions - TradingView — Track All Markets
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon - TradingView — Track All Markets
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings? - The Globe and Mail
AbbVie, RemeGen Partner on Novel Bispecific Antibody for Advanced Tumors - Contract Pharma
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie’s $100 Billion Gamble: A Strategic Trade With Washington to Lower Drug Costs - abacusnews.com
AbbVie Secures Tariff Relief Pact - GuruFocus
AbbVie pledges $100B to US production in drug pricing deal with Trump - BioPharma Dive
AbbVie and China’s RemeGen kick off year with $5.6bn oncology deal - BioXconomy
AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions - BioSpace
AbbVie reaches 3-year deal with White House to lower drug prices - MSN
AbbVie inks MFN drug pricing deal, pledges $100bn to US R&D - Pharmaceutical Technology
AbbVie adds Arizona plant to $10bn US manufacturing push - The Pharma Letter
Abbvie, US reach agreement to cut drug prices - WHTC
AbbVie Stock Rises After $100 Billion Deal With Trump. It Will Avoid Tariffs. - Barron's
ZAWYA-PRESSR: Ministry of Health and Prevention launches "Mental Health 360" campaign in collaboration with AbbVie - TradingView — Track All Markets
Remegen stock rating upgraded by JPMorgan on AbbVie licensing deal - Investing.com Canada
AbbVie reaches deal with Trump administration on drug prices in exchange for tariff relief - Yahoo Finance
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules - BioSpace
AbbVie (ABBV) Strikes $100 Billion Deal with Trump Administratio - GuruFocus
AbbVie secures tariff relief in drug pricing deal, pledges $100B investment (ABBV:NYSE) - Seeking Alpha
AbbVie pledges $100 billion U.S. investment to avoid tariffs - Crain's Chicago Business
AbbVie Pledges $100 Billion US Investment to Avoid Tariffs - Bloomberg.com
AbbVie Puts Up $650M to Join Emerging But Crowded Area of Cancer Drug R&D - MedCity News
AbbVie to cut drug prices, pledges $100 billion for research - marketscreener.com
AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices - The Wall Street Journal
AbbVie (ABBV) Commits to Boosting U.S. Healthcare and Innovation - GuruFocus
Abbvie reaches deal with Trump admin to cut drug prices, invest $100 bln in US By Investing.com - Investing.com
AbbVie strikes deal with Trump administration on drug pricing By Investing.com - Investing.com Canada
AbbVie announces voluntary agreement with the Trump administration - TipRanks
JPM Day 1: Big bucks for bispecific - biocentury.com
Millions of Americans to see lower drug costs in new AbbVie–Trump pact - Stock Titan
AbbVie Becomes Latest To License PD-1xVEGF Bispecific In Growing Field - Citeline News & Insights
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Chicago's AbbVie to acquire Tempe medical device manufacturing facility - The Business Journals
Key facts: AbbVie partners with RemeGen; acquires West Pharma rights - TradingView — Track All Markets
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy - TechStock²
AbbVie inks $5.6 billion oncology deal with Chinese pharma - Crain's Chicago Business
AbbVie punts up to ~$5 billion on RemeGen bispecific antibody - The Pharma Letter
JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement - Yahoo Finance
AbbVie partners with China's RemeGen on experimental tumor treatment - Reuters
Leerink Partners Adjusts AbbVie Price Target to $245 From $243, Maintains Outperform Rating - marketscreener.com
Analyst recommendations: Exxon Mobil, AbbVie, Eli Lilly, JD Sports… - marketscreener.com
AbbVie (ABBV) Secures Global Rights to RemeGen's RC148 - GuruFocus
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense - The Globe and Mail
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):